Evidence map›Paper›PMID 36632289›Full record

ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2022

Midsize noncoding RNAs in cancers: a new division that clarifies the world of noncoding RNA or an unnecessary chaos?

Kacper Guglas, Joanna Kozłowska-Masłoń, Tomasz Kolenda, Anna Paszkowska, Anna Teresiak, Renata Bliźniak, Katarzyna Lamperska

Open access · diamondAbstract readReview
In one paragraph

Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Biomedicines · 2026
    Article
  2. lncRNA EGOT across cancers: TCGA analysis.Archives of medical science : AMS · 2026
    Article
  3. Article
  4. Article
  5. lncRNABiomedicines · 2025
    Article
  6. Pseudogenes in the carcinogenesis: epithelial-to-mesenchymal transition process and cancer initiating cells.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Review
  7. Review
  8. Diagnostic Potential ofInternational journal of molecular sciences · 2024
    Article
  9. Article
  10. Review
  11. The RNA world: from experimental laboratory to "in silico" approach. Part 1: User friendly RNA expression databases portals.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Review
  12. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Article
  13. Current issues in molecular biology · 2023
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kacper GuglasLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Joanna Kozłowska-MasłońLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Tomasz KolendaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Anna PaszkowskaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Anna TeresiakLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Renata BliźniakLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Katarzyna LamperskaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Greater Poland Cancer Center · PLAdam Mickiewicz University in Poznań · PLPostgraduate School of Molecular Medicine · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most of the human genome is made out of noncoding RNAs (ncRNAs). These ncRNAs do not code for proteins but carry a vast number of important functions in human cells such as: modification and processing other RNAs (tRNAs, rRNAs, snRNAs, snoRNAs, miRNAs), help in the synthesis of ribosome proteins, initiation of DNA replication, regulation of transcription, processing of pre-messenger mRNA during its maturation and much more. The ncRNAs also have a significant impact on many events that occur during carcinogenesis in cancer cells, such as: regulation of cell survival, cellular signaling, apoptosis, proliferation or even influencing the metastasis process. The ncRNAs may be divided based on their length, into short and long, where 200 nucleotides is the "magic" border. However, a new division was proposed, suggesting the creation of the additional group called midsize noncoding RNAs, with the length ranging from 50-400 nucleotides. This new group may include: transfer RNA (tRNA), small nuclear RNAs (snRNAs) with 7SK and 7SL, small nucleolar RNAs (snoRNAs), small Cajal body-specific RNAs (scaRNAs) and YRNAs. In this review their structure, biogenesis, function and influence on carcinogenesis process will be evaluated. What is more, a question will be answered of whether this new division is a necessity that clears current knowledge or just creates an additional misunderstanding in the ncRNA world?

Indexed as

cancermidsize noncoding RNAnoncoding RNAscaRNAsnoRNAsnRNAtRNAYRNA

Identifiers

PMID36632289
PMCPMC9826665
OpenAlexW4313303824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.